Bristol Myers Squibb stock steadies as Q2 2026 growth meets new Camzyos data

Published on 08/30/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock is trading in the mid-$60s as investors weigh Q2 2026 earnings growth against fresh five-year Camzyos data presented at ESC Congress 2026.

Architektonische Innenaufnahme einer modernen pharmazeutischen Bioprozessanlage mit glänzenden Edelstahl-Bioreaktortanks, kühlen blauen Tönen und polierten Böden — Bristol-Myers Squibb US0897961004 Architekturaufnahme moderner pharmazeutischer Bioreaktor-Produktionshalle mit Edelstahltanks in steriler Umgebung, Illustration mit AI erstellt.

Bristol Myers Squibb Inc. (ISIN US0897961004) stock recently closed at $66.58 on August 28, 2026, in New York Stock Exchange trading, as investors digest Q2 2026 earnings growth alongside new five-year data for the heart drug Camzyos presented at a major cardiology congress.

The latest quarter showed that Bristol Myers Squibb generated $12.97 billion in revenue in Q2 2026, a 6 percent increase compared with Q2 2025, while non-GAAP earnings per share rose to $2.04 from $1.46, underscoring that profitability is growing faster than sales.

This combination of steady share price in the mid-$60 range and solid earnings momentum sets the stage for how the market is valuing the company as it deepens its focus on growth therapies such as Camzyos.

Q2 2026 earnings show operating leverage

Recent summaries of Bristol Myers Squibb's most recent quarter indicate that for Q2 2026 the $12.97 billion in revenue represented 6 percent year-over-year growth, or 5 percent growth after adjusting for foreign exchange effects. This indicates that core demand, rather than currency swings, is the primary driver of the top line.

On the earnings side, non-GAAP earnings per share of $2.04 in Q2 2026 compared with $1.46 in Q2 2025, while GAAP EPS increased to $1.62, meaning that earnings per share grew markedly faster than revenue as margins benefited from product mix and cost discipline. The move from $1.46 to $2.04 on a non-GAAP basis represents an increase of 0.58 per share over one year.

Within the company's revenue mix, the growth portfolio delivered $7.6 billion in sales in Q2 2026, which is a 15 percent increase compared with the prior-year quarter, a pace that comfortably exceeds the 6 percent overall revenue growth for the group. In contrast, the legacy portfolio generated $5.4 billion in revenue in Q2 2026, down 4 percent year-over-year, showing how older medicines are facing ongoing generic and biosimilar competition.

For investors, the fact that earnings per share expanded from $1.46 to $2.04 on a non-GAAP basis in one year, while overall revenue increased by 6 percent and growth-platform revenue rose 15 percent, highlights that Bristol Myers Squibb's portfolio transition toward newer therapies is supporting operating leverage and profitability even as legacy products decline.

Stock valuation against recent trading levels

According to recent New York Stock Exchange market data as of 4:00 p.m. ET on August 28, 2026, Bristol Myers Squibb stock closed at $66.58, with a modest 0.55 percent decline on the day before ticking slightly higher to $66.60 in after-hours trading. This places the shares in the mid-$60 range that has characterized recent sessions.

That price level has been discussed in the context of at least one referenced fair-value estimate of $62.96, implying that the market price of $66.58 at the August 28, 2026 close stood modestly above that valuation benchmark by several dollars. For investors, a stock price sitting a few dollars higher than such an estimate can suggest that the market is factoring in continued growth from the company's newer therapies and confidence in its earnings trajectory.

Viewed together, the $66.58 closing price, the $12.97 billion Q2 2026 revenue figure with 6 percent year-over-year growth, and non-GAAP EPS of $2.04 versus $1.46 in the prior-year quarter frame how the equity market is currently valuing Bristol Myers Squibb's transition toward a higher-growth portfolio and an improving earnings profile.

Five-year Camzyos data at ESC Congress 2026

Bristol Myers Squibb has also been highlighting the long-term performance of Camzyos, its cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy, with a late-breaker presentation at the European Society of Cardiology Congress 2026 in Munich on August 29, 2026. A company communication reported that results from the EXPLORER-LTE cohort of the MAVA-LTE study demonstrated sustained efficacy and safety for patients followed for as long as five years.

A same-day analysis noted that the five-year data set for Camzyos showed consistent improvements in functional capacity and symptoms for obstructive hypertrophic cardiomyopathy patients, with no new safety concerns emerging in either the long-term clinical follow-up or real-world evidence across global populations. This reinforces Camzyos as one of the most extensively studied cardiac myosin inhibitors in contemporary cardiology and underscores its strategic importance within Bristol Myers Squibb's growth portfolio.

The Camzyos update interacts directly with the Q2 2026 financial picture, because newer therapies collectively delivered $7.6 billion in revenue in that quarter, a 15 percent year-over-year increase, and Camzyos sits within this cohort of expanding treatments. As long-term data support durable benefit and safety, investors can connect the clinical narrative to the revenue-growth figures that are already visible in the latest reported quarter.

Portfolio balance between growth and legacy medicines

Bristol Myers Squibb's revenue composition in Q2 2026 illustrates how the business is managing the balance between expanding growth assets and maturing legacy products. Growth-platform revenue of $7.6 billion, up 15 percent year-over-year, reflects strong uptake in areas such as cardiology, oncology, and immunology, while the $5.4 billion legacy revenue segment fell 4 percent compared with Q2 2025.

This numerical split shows that the growth portfolio already accounts for a majority of total quarterly revenue, with $7.6 billion from growth therapies versus $5.4 billion from legacy products in Q2 2026. The fact that growth assets are expanding at a double-digit rate while legacy products are declining mid-single digits highlights that Bristol Myers Squibb's strategy is increasingly driven by newer medicines.

In that context, Camzyos is emblematic of the company's push into targeted, mechanism-based treatments. The five-year EXPLORER-LTE data shared at ESC Congress 2026 align with the notion that growth assets can sustain both clinical relevance and revenue contribution over long periods, which is critical for offsetting the impact of generic erosion on older blockbuster drugs.

Camzyos as a representative product

Camzyos (mavacamten) is a cardiac myosin inhibitor developed by Bristol Myers Squibb for adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle impairs blood flow. The therapy is designed to modulate the contractility of heart muscle by targeting myosin, thereby relieving obstruction and improving symptoms such as shortness of breath and chest pain.

The EXPLORER-LTE cohort of the MAVA-LTE study, featured in the late-breaking session at ESC Congress 2026 on August 29, 2026, adds up to five years of follow-up on patients receiving Camzyos. In this long-term data set, investigators reported sustained improvements in functional capacity, preserved left ventricular ejection fraction, and consistent symptom relief, with adverse events aligned with the known safety profile and no new safety signals emerging.

For Bristol Myers Squibb, Camzyos represents a strategic bridge between cardiology innovation and earnings growth. The product contributes to the $7.6 billion growth-portfolio revenue figure reported for Q2 2026, and the demonstrated durability of benefit over several years can support physician confidence, patient adherence, and payer acceptance, which collectively underpin the revenue trends highlighted in recent financial updates.

Latest trading context for Bristol Myers Squibb stock

As of the regular trading session close at 4:00 p.m. ET on August 28, 2026, Bristol Myers Squibb stock traded at $66.58 on the New York Stock Exchange, with after-hours trading indicating a slight uptick to $66.60. This places the shares modestly above one referenced fair-value mark of $62.96, suggesting a valuation that bakes in a degree of optimism around earnings and growth assets.

While detailed intraday percentage moves on August 30, 2026 are not fully enumerated in the available sources, the indicated 0.55 percent decline on August 28, 2026 shows that the stock's day-to-day fluctuations have recently been in a relatively narrow band around the mid-$60s level. For investors tracking the name, this trading range functions as a reference point against which to measure future reactions to upcoming earnings updates, regulatory developments, or additional data releases for drugs such as Camzyos.

In the broader context of Bristol Myers Squibb's Q2 2026 numbers, a mid-$60 share price combined with $12.97 billion in quarterly revenue and non-GAAP EPS of $2.04 versus $1.46 a year earlier indicates that the market is assigning a valuation that reflects both the challenges of legacy-drug erosion and the opportunities represented by the growth portfolio and long-term clinical data.